Recent evidence suggests that ovarian high-grade serous carcinoma (HGSC) originates from the epithelium of the fallopian tube. However, most mouse models are based on the previous prevailing view that ovarian cancer develops from the transformation of the ovarian surface epithelium. Here, we report the extensive histological and molecular characterization of the mogpTAg transgenic mouse, which expresses the SV40 large T-antigen (TAg) under the control of the mouse müllerian-specific Ovgp-1 promoter. Histologic analysis of the fallopian tubes of mogpTAg mice identified a variety of neoplastic lesions analogous to those described as precursors to ovarian HGSC. We identified areas of normal appearing p53-positive epithelium that are similar to "p53 signatures" in the human fallopian tube. More advanced proliferative lesions with nuclear 
Introduction
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy accounting for nearly 15 ,000 deaths annually in the US, yet the mechanisms of its origin, initiation, and progression remain unclear. In particular, the tissue of origin of EOC has recently become a matter of debate. The ovarian surface epithelium (OSE), a relatively undifferentiated layer of mesothelial cells, has been thought to be the cell of origin, but this theory has several weaknesses [1, 2] . First, precursor lesions of ovarian high-grade serous carcinoma (HGSC), which accounts for the vast majority of EOC, have rarely been identified in the ovary. Second, the various types of EOC have a müllerian origin and phenotype, resembling the epithelia of the endometrium and fallopian tube (FT). In contrast, the ovaries are not müllerian, but rather originate from the genital ridge. Third, in order to account for the similarity of HGSC to FT epithelium, it has been argued that the OSE first undergoes a metaplastic change to tubal-type epithelium before undergoing malignant transformation.
Recently, meticulous reexamination of the FT from women with a predisposition to ovarian cancer has identified malignant lesions in the FT, including early noninvasive precursor lesions of HGSC termed "serous tubal intraepithelial carcinomas" (STICs) [3, 4] . Importantly, STICs have been linked to the development of serous ovarian cancer based on the observation that up to 60% of the patients with sporadic ovarian carcinomas also have STICs in their FTs [5] . In addition, when HGSC and STICs coexist, they exhibit identical p53 mutations [5, 6] . Moreover, morphologically normal-appearing areas of FT epithelium that exhibit p53 staining (termed "p53 signatures") have been identified in the tubal epithelium and it has been proposed that they represent a precursor to STICs [7] . Taken together, these recent findings suggest a model of ovarian tumorigenesis by which tubal epithelium gives rise to early intraepithelial carcinomas, which can then spread and implant on the ovary, where they grow and therefore appear to be primary ovarian neoplasms. This theory recapitulates many of the pathologic and morphologic features of human HGSC, including the lack of precursor lesions in the ovary and the histological appearance of HGSC, which resembles FT epithelium.
The majority of genetically engineered mouse models of EOC target the transformation of OSE using various approaches [8] [9] [10] [11] [12] . Just recently, Perets et al. reported mouse models with FT transformation that develop high-grade serous tumors that frequently metastasized to the ovary and peritoneum [13] . In light of the evidence for the new paradigm described above, it is crucial to continue to develop mouse models of FT transformation. Here, we report the further characterization of another transgenic mouse, mogp-TAg, which spontaneously develops neoplastic lesions in the FT epithelium and the endometrium [14] . We show that the mouse develops tubal lesions expressing many of the same markers as human STICs and that the transformed FT epithelium often invades the ovary to form tumors similar to human ovarian HGSC. Microarray analysis of the mouse tubal lesions identifies many altered genes and the expression of one of these genes, Top2A, is shown to be elevated in mouse and human STICs and may represent a novel early marker in ovarian cancer development.
Materials and Methods

Transgenic mouse
The generation of the mogp-TAg transgenic mouse has been described [14] . Female mice were euthanized at various ages using carbon dioxide inhalation followed by cervical dislocation. The animal protocol was approved by the NIA animal care and use committee.
Tissues
Mouse tissues were either snap frozen for RNA isolation, or fixed in 10% formalin for paraffin embedding. Human archived formalin fixed embedded tissue cases were retrieved from the Johns Hopkins Medical Institutions. 6 STICs, 59 HGSC, 8 low-grade serous carcinomas (LGSC), and 8 normal FTs were included in this study. Tumor tissue was arranged in tissue microarrays. Triplicate 1 mm representative cores were obtained from each tumor block and arrayed on a recipient paraffin block. The collection of specimens was performed in accordance with an approved IRB.
Real-Time RT-PCR
Total RNA was extracted from tissues using Trizol according to the manufacturer's protocol (Invitrogen). Reverse Transcription of 1 μg of total RNA was performed using Taqman Reverse Transcription (Invitrogen). A normal mouse cDNA panel was also used (MNRT 101, OriGene). Primers were designed to amplify the mouse oviductal glycoprotein 1 gene (Ovgp-1): ctccacacttgccaaccg (Ovgp1_m2-F) and cataagacgtatggatgatgc (Ovgp1_m2-R). Levels of Ovgp-1 were analyzed by quantitative real-time PCR using SYBR Green Mix (Roche) normalized to mouse Gapdh as previously described [15] . Data was analyzed using the comparative Ct method [16] .
Immunohistochemistry (IHC)
IHC of mouse tissues, was accomplished using the Labvision (Fisher) anti-rabbit protocol for the following antibodies: anti-Ki67 at 1:300 (Novus Biologicals); anti-p53 at 1:500 (Santa Cruz); anti-TAg at 1:500 (Santa Cruz); anti-H2AX at 1:500 (Cell Signaling); anti-PAX8 at 1:600 (ProteinTech); anti-Top2A at 1:200 (Epitome) and anti-PBK at 1:25 (Cell Signaling) [17] . For human tissues, IHC was performed as previously described [16] . Briefly, the slides were incubated with antibody against Top2a (Novus Biologicals, cat# NB110-57623) and EnVision™+/HRP Rabbit polymer (Dako, cat# K4003) was then applied. IHC expression for Topoisomerase II Alpha was evaluated as the average percentage of nuclear positive tumor cells on 3 tissue cores of the tissue array.
Illumina microarray analysis
Total RNA was extracted from the FTs of three wild-type C57BL/6 mice and three mogpTAg mice using Trizol (Invitrogen). Biotinylated cRNA was prepared from 500 ng of RNA using the Illumina RNA Amplification Kit (Ambion). The cDNA was hybridized to a MouseRef-8 Expression BeadChip (Illumina). Microarray data analysis was performed as previously described [18] . Expression changes for individual genes were considered significant if they met 4 criteria: z-ratio above 1.5; false detection rate <0.30; p-value of the pairwise t-test<0.05; and mean background-corrected signal intensity z-score in each comparison group is not negative [19] . Principal component analysis was conducted based on the above values using JMP software (SAS) to generate a 3D scatterplot with percent variance. These data have been deposited in NCBI's Gene Expression Omnibus and is accessible through GEO Series accession number GSE52011 (http:// www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE52011). Ingenuity Pathway Analysis (IPA) was also conducted, looking at both canonical pathways and biological functions (Ingenuity® Systems).
Statistical analysis
Comparisons of IHC outcomes were performed using the two-tailed unpaired t-test. p-values of 0.05 or less were considered statistically significant. Statistical analysis was carried out using GraphPad Prism software (GraphPad Software).
Results
TAg expressing transgenic mouse
Gene expression profiling data showed that OVGP1 is highly expressed in the epithelium of the human FT, but is found at much lower levels in other tissues (data not shown). In order to assess the value of the Ovgp1 promoter in a mouse model of FT transformation, we evaluated the expression pattern of Ovgp1 in 34 mouse tissues by real-time RT-PCR. We found that Ovgp1 is expressed 45-fold higher in the FT compared to any other female tissue (Supp. Fig. 1 ). The testis expressed the highest levels of Ovgp1 in males, albeit at a lower level than in FTs. We therefore hypothesized that the Ovgp1 promoter may be used to specifically induce tumorigenesis in the FT through expression of the TAg. We decided to further characterize the previously reported mogp-TAg mouse, which expresses TAg from the mouse Ovgp1 promoter [14] . Starting at approximately 6 weeks of age, tumors of the female genital tract were found in mogp-TAg females. As the females aged, we observed an increase in size of both the uterus and the FTs.
Histopathologic and immunohistochemical analysis of the FTs
Analysis of the FTs of mice 7-12 weeks of age, led to the identification of lesions that were overtly malignant, characterized by epithelial stratification and marked nuclear atypia, including mitotic bodies, enlarged nuclei, and irregular chromatin, resembling what has been described as STICs in human FTs [20] [21] [22] (Fig. 1) . A human STIC is shown in inset for comparison. These lesions, which we refer to as mSTICs, were positive for p53 and expressed the TAg. Similar to what is observed in human STICs, mSTICs were also highly proliferative as ascertained by Mib-1 (Ki-67) staining (Fig. 1 ).
Because of reports describing "p53 signatures" in human HGSC, [7, 22, 23] we searched for similar lesions in this model. We identified areas in the FT mucosa of mice between 6-9 weeks of age that exhibited intense p53 staining, but did not show morphological signs of a carcinoma (Fig. 2) . Again, TAg staining was restricted to a small area that corresponded to the p53 staining. The mouse p53 signature shown in Fig. 2 exhibited high proliferation, as most of the cells present in the lesion were Mib-1 positive. p53 signatures and mSTICs were observed in all the mice examined except older mice (13 weeks) where the presence of advanced epithelial lesions had completely destroyed the tissue. The stroma of mogp-TAg mice exhibited staining of both TAg and Mib-1 (Figs 1 and 2 ), while the WT mice did not (data not shown).
Invasive adenocarcinoma in the ovary
In addition to tubal lesions, adenocarcinomas were detected in the ovaries of 56% of mogpTAg mice examined between the ages of 8-10 weeks (Fig. 3) . No adenocarcinomas were found in younger mice. The invasive carcinomas were positive for TAg and p53, and exhibited a high proliferation index, as determined by Mib-1 staining. Interestingly, these carcinomas were positive for PAX8, a müllerian/FT marker, while the surrounding ovarian tissues, including the OSE, were negative. The invasive cancers also stained positively for γ-H2AX, a marker of DNA damage that has been shown to be positive in human STICs and in serous cancers [24] . It is interesting to note that all mice with HGSCs also had p53 signatures and STICs in their FTs.
Gene expression profiling of neoplastic FTs
In order to better understand the molecular mechanism of tumorigenesis in the FT, we compared gene expression profiles of FT from mogp-TAg mice with WT age-matched FTs. Microarray analysis identified a large number of genes whose expression was altered in mogp-TAg FT. Principal Component Analysis (PCA) revealed a distinct gene expression pattern between the FT from mogp-TAg mice and WT mice (Fig. 4) . We chose to focus our attention on genes that were elevated in the diseased FT, as we hypothesized that these genes may represent useful biomarkers for mSTICs and mouse p53 signatures, and possibly provide insight into the mechanisms of HGSC initiation. Table 1 lists the top 20 most highly up-regulated genes in mogp-TAg FT compared to WT FT. Six of these genes have previously been reported to be regulated by p53, which highlights this prominent signaling mechanism in the neoplastic FT tissues. IPA analysis revealed alterations in many Canonical pathways (Supp. Fig. 2 , Supp. Table 1 ). As expected, p53 Signaling was affected (Supp. Fig.  3 , Supp. Table 2 ). The most significantly modified pathways included Cell Cycle Control of Chromosomal Replication (Supp. Fig. 4 , Supp. Table 3 ) and the Role of BRCA1 in DNA Damage Response (Supp. Fig. 5 , Supp. Table 4 ). Also, expression patterns seen in biological outcomes (Ingenuity defined functions) (Supp. Fig. 6 ) such as cancer, and reproductive system diseases were identified.
Topoisomerase II alpha is elevated in mouse high-grade serous lesions
Tumorigenesis is initiated by p53 inactivation in this model and is a very early event in human serous carcinoma development as well. Therefore, we were particularly interested in the p53-regulated genes identified as altered in mogp-TAg FT, as they may represent genuine targets of p53 in serous carcinoma development. In particular, we focused on PDZ binding kinase (Pbk) and Topoisomerase II alpha (Top2a), which have previously been implicated in human cancer [25, 26] . We performed IHC for PDZ binding kinase and Topoisomerase II alpha on mouse sections from WT and mogp-TAg FT. Pbk staining did not show reproducible patterns (data not shown), and was not investigated further. Top2a exhibited strong staining in mSTICs and in the invasive portion of the tumor (Fig. 5 ). In particular, there was a striking correlation between the expression of Top2a and the expression of p53 in these samples, suggesting strongly that Top2a is regulated by p53 in this HGSC model. The signaling involved is highlighted in the IPA pathway analysis finding, G2/M DNA Damage Checkpoint Regulation (Supp. Fig. 7 , Supp. Table 5 ).
Topoisomerase II alpha is elevated in human high-grade serous lesions
In order to determine whether TOP2A was also expressed in human serous carcinoma, we stained human STICs and serous carcinoma for Topoisomerase II alpha expression (Fig. 6) . Human STICs and HGSCs exhibited strong diffuse staining of Topoisomerase II alpha, while LGSC cells exhibited sparse staining at best and normal FT cells were negative. The transition in staining between normal FT and STIC was particularly striking, with a complete absence of staining in normal FT transitioning to strong staining in the STIC (Fig.  6 ). Quantitative analysis of 8 normal human FT epithelium (NFT), 8 LGSCs , 59 HGSCs, and 6 STICs demonstrated statistically significant differences in Topoisomerase II alpha expression between NFT and LGCS (P=0.0001), HGSC (P=0.0039), and STICs (P=0.0013) (Fig 6F) . In addition, statistically significant differences were found between LGSC and both STICs (P=0.0054) and HGSC (P=0.011). There was no significant difference in the between STIC and HGSC (P=0.40).
Discussion
Technological advances have allowed the development of genetically engineered mouse models that recapitulate genotypic and phenotypic features of human cancers [27] . In ovarian cancer, multiple genetically engineered mouse models have been reported but, because of the prevailing view that HGSCs develop from the ovarian surface epithelium, most are based on the transformation of mouse OSE.
Recently, a series of morphologic, immunohistochemical and molecular studies have suggested that epithelial cells in the distal tube (fimbria) give rise to ovarian (pelvic) HGSC [28, 29] . According to this theory, secretory cells in the tube can clonally proliferate, and through a series of intermediate steps, give rise to intraepithelial serous carcinoma, which can either invade the tube before spreading to the ovary, or can shed cells that implant directly on the ovary and surrounding pelvic structures. Here, we present a transgenic model which expresses the TAg from the mouse Ovgp1 promoter, a müllerian-specific promoter highly active in the FT. The use of the TAg in the induction of FT carcinogenesis is appropriate, considering that p53 inactivation appears to be one of the earliest events in this cancer [29] . While the OVGP promoter is ideal for targeting the TAg to the fallopian tube, its activity is dependent on estrogen. Subsequently, the expression of TAg corresponds with sexual maturity of the mice and with the onset of the serous lesions in our model. The ability to control TAg expression could actually be quite useful. In principle, this could be done by performing an ovariectomy on young mice to inhibit estrogen production and then add estrogen artificially to induce tumorigenesis.
The TAg used in our mouse model binds p53 and is thought to completely inactivate the protein, leading to a p53-null phenotype (although the p53 protein accumulates due to a lack of degradation of the complex). The majority of p53 mutations observed in ovarian cancer are point mutations that also lead to protein inactivation and accumulation. However, based on several lines of evidence, mutant p53 protein may have residual activity or even acquire novel activities that promote transformation. Therefore, our model may not be completely representative of the p53 phenotype in the majority of ovarian cancers. However, it is important to realize that up to 30% of ovarian cancer have a null p53 phenotype indicating that complete p53 inactivation is indeed a mechanism that is observed with this disease [30] . It has been suggested that, while the gain-of-function mutations of p53 may not be essential for tumor development, they may be important in some other aspects of tumorigenesis such as drug resistance.
It is important to note that the large T antigen inactivates both p53 and Rb. While the Rb gene itself is not frequently mutated in ovarian cancer, the Rb pathway is likely altered in a large proportion of ovarian cancers. Indeed, mutations in INK4, RB, or CDK4 were observed in almost fifty percent of ovarian samples [31, 32] . In addition, specifically analyzing p16 expression and alteration, numerous studies have reported changes in up to 65% of ovarian cancers. Inactivation of pRB in addition to p53 in our model may therefore be consistent with human ovarian tumorigenesis.
Examination of the FT of the mogp-TAg mice revealed the presence of several neoplastic lesions, including a mouse equivalent to the human STIC, mSTIC. In addition, we also found morphologically normal lesions that stained for p53, analogous to the p53 signatures in humans. Similar to what is observed in human p53 signatures, we believe that the accumulated p53 in the mouse is non-functional, as it is bound to the large TAg. Interestingly, the TAg expression showed patterns identical to the p53 signatures, which indicates that the pattern of p53 stabilization and inactivation is due to the variations in the expression or binding of the TAg. The mouse p53 signatures were proliferative as determined by Ki-67 staining. Proliferative p53 signatures have been identified in human FTs and are thought to be an intermediate step between p53 signatures with low Ki-67 and STICs, which typically have a high proliferation index [29] . While the p53 signature patterns cannot be explained at this time, they nonetheless make this mouse model quite interesting as it appears to be very similar to the of early ovarian cancer development. Another particularly provocative finding was the observation of adenocarcinomas within the ovary. Nine of the 16 mice we examined contained a carcinoma implant in one or both ovaries. All were positive for PAX 8 expression, a müllerian marker found overexpressed in human ovarian HGSC [33] , and for γ-H2AX, a marker of DNA damage also found expressed in serous cancer [34] . Overall, these findings are consistent with the theory suggesting that human ovarian HGSC originates in the FT. While it is possible that the carcinoma observed within the mouse ovaries originated in the OSE, we believe it is unlikely for several reasons: 1) we did not observe TAg expression in any other areas of the ovary, including the OSE, 2) the carcinomas in the ovary were positive for PAX8, a known marker of müllerian tissues that is negative in OSE [35] , and 3) despite extensive serial sectioning, we did not find continuity between the ovarian carcinoma and the OSE.
The majority of previous ovarian cancer mouse models relied on OSE transformation and yielded either undifferentiated or poorly differentiated carcinomas [9, 11, 36] , endometrioid carcinomas [36, 37] , cystic adenocarcinomas [10] and leiomyosarcomas [37] [38] [39] [40] but not high grade adenocarcinomas as seen in humans and the mogp-TAg mouse. While these mice have taught us a great deal about OSE transformation, the findings are not surprising considering that the OSE is mesothelial in nature and not müllerian as the majority of EOC appear. The mogp-TAg mouse is not the only model that targets FT epithelium. Kim et al. [41] reported a conditional knock out of Dicer and Pten in tubal epithelium that was shown to produce carcinomas and metastasis. However, the primary tumors were reported to arise from the FT stroma not the epithelium, which is not believed to be the case in human HGSC.
More recently, a study demonstrated that deletion of Trp53, Pten, and Brca1/2 in the FT secretory cells leads to HGSC that frequently metastasized to the ovary [13] . This finding is consistent with our model, which shows that FT transformation can lead to HGSC and serous carcinoma to the ovary. A feature of the mogp-TAg mouse is that it exhibits easily identifiable precursor lesions (p53 signatures and STICs). The presence of these precursors in the FT is particularly important because it can potentially shed light on the early events of high-grade serous tumorigenesis.
The Ovgp1 promoter used for TAg expression was specific as we did not observe cancer outside the genital tract in females. However, the FT stroma was found to express TAg and Mib-1. While we did not observe neoplastic lesions in the FT stroma, the ovarian stromal compartment has been suggested to affect tumor progression, and therefore the behavior of the epithelial FT cells may be affected by the abnormal TAg expressing stroma. This model may therefore be useful in the study of the effects of the environment in ovarian cancer initiation and development. In addition, examination of the uterus of older mice also revealed neoplastic lesions. We observed non-invasive malignant lesions, reminiscent of endometrial intraepithelial carcinoma (EIC) (data not shown), the precursor of uterine serous carcinoma (USC) in humans. Finally, we did observe non-invasive sarcomas in the uterus of older mice, which is consistent with the observation that this stroma also expresses the TAg.
While the sarcoma is certainly an unwanted byproduct of Ovgp1-mediated TAg expression, we do not believe that it affects the epithelial phenotype seen in the model.
The gene expression patterns were clearly different between normal and diseased tissue (Fig.  4) , which allowed the identification of multiple genes and pathways abnormally regulated in the mogp FTE. IPA revealed that cell cycle control and DNA damage response pathways were altered in the FT of mogp-TAg mice. This is consistent with our strategy for inducing tumorigenesis, inactivation of p53, but also with the known mechanisms of ovarian cancer initiation and development. Moreover, the p53 pathway itself was prominently deregulated with multiple downstream genes abnormally expressed. Top2a, a gene previously shown to be regulated by p53 [42] and implicated in breast cancer development [25, 43] , was shown to be elevated in mSTICs, the early HGSC lesions identified in our mouse model. TP53 and Top2a were concurrently expressed in the lesions, a finding consistent with previous observations made in advanced ovarian cancer samples [44] . Most interestingly, we also found TOP2A elevated in human STICs and ovarian cancer, not only validating our mouse model as relevant to human ovarian cancer, but also identifying a new biomarker for early serous lesions. TOP2A is a target for anthracyclines, such as doxorubicin, a drug used in platinum-refractory ovarian cancer and its expression has been associated with poor survival and platinum resistance in ovarian cancer [45] . It has also been reported that TOP2A is elevated in tumor-adjacent stroma cells, but decreased in tumor cells following chemotherapy [46] , suggesting that TOP2A may also have an important role in the stroma. In any case, our model may represent a useful tool to study the roles of TOP2A in ovarian cancer development and drug resistance.
In summary, we report a new ovarian cancer model based on transformation of FT epithelium. The model exhibits features strongly reminiscent of STICs in humans and, importantly, also displays serous adenocarcinoma implants in the ovary. The model may therefore represent a useful tool for the study of ovarian cancer progression. In addition, since the model recapitulates the earliest events in serous ovarian cancer development, it may be useful in the identification of novel strategies for prevention as well as for treatment of this disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. H&E of the ovary a 10 week old mouse shows the pathological features of the invasive serous carcinoma that include papillary structures and condensed chromatin. TAg IHC is strongly positive in the stratified epithelium of the invasive carcinoma. The carcinogenic area also demonstrates strong staining for p53, Ki-67, the müllerian marker PAX8 and γ-H2AX. 56% of the mice examined have similar carcinomas in their ovaries. LGSC, HGCD and STICs. There is also a significant difference between LGSC and both STICs and HGSC. There is no significant difference between STIC and HGSC.
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